Browse
Submit Data
Databases
API
Help

Dataset Information

235 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Trial of colonic stenting for large bowel obstruction

ABSTRACT: Interventions: This study will compare the outcomes of colorectal surgery (bowel resection and possible stoma formation) versus colonic stent insertion using Ultraflex or Wallfex Precision Colonic Stent manufactured by Boston Scientific (TGA approved in Australia) to determine optimal management of non-curable colorectal cancer. Comparisons will be made between quality of life, length of stay, complications and cost to identify which group has the optimal outcome. The study will be conducted over 3 years. Primary outcome(s): To compare quality of life between surgical intervention and colonic stent insertion in the first 12 months following the procedure.[Daily until discharge from hospital, then at 1, 2, and 4 weeks and 3, 6 and 12 months] Study Design: Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Open (masking not used);Assignment: Factorial;Type of endpoint: Efficacy

DISEASE(S): Large Bowel Obstructions,Colorectal Cancers,Cancer-bowel-back Passage (rectum) Or Large Bowel (colon)

PROVIDER: 2452794 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Outcome of Palliative Management of Malignant Large Bowel Obstruction w/Colorectal Stents or Surgery

Project description:The purpose of this study is to assess quality of life and bowel symptoms after treatment.The main objective is to compare the effect on quality of life of minimally invasive bowel surgery and endoscopic stent placement in the treatment of malignant large bowel obstruction.

| 2015060 | ecrin-mdr-crc

TRANSIT study

Project description:Interventions: Colonoscopy for obstructive colorectal cancer after insertion of seif-expandable metal stent Primary outcome(s): Detection rate of synchronous colorectal cancer in the proximal side Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, diagnostic purpose

| 2723039 | ecrin-mdr-crc

Effects of TNFR1 deletion in mice in early life

Project description:Athough anti-TNF therapies can be used to treat colitis associated with inflammatory bowel disease, in mice the loss of the TNF receptor TNFR1 (Tnfrsf1a) in the Il10-/- spontaneous colitis background results in acceleration of disease onset. Whereas Il10-/- mice on the Bl/6 background are relatively protected from colitis throughout life, Il10-/- Tnfr1-/- mice develop colitis beginning at 4 wks of age. Their disease results in nearly 50% mortality by 12 wks of age. Strikingly, Tnfr1-/- mice (with functional IL-10) exhibit evidence of mucosal dysfunction at 4 and 12 wks of age. These mucosal abnormalities include loss of barrier integrity, increased epithelial cell proliferation, crypt malformations, and increased immune cell infiltrate. Because of the early onset of mucosal abnormalities in Tnfr1-/- mice, with or without IL-10 expression, we hypothesized that TNFR1 plays important roles in colonic mucosal function in early life, prior to weaning. To test this hypothesis, we profiled, using mRNA-Seq, the colonic transcriptomes from wildtype and Tnfr1-/- mice at 2 wks of age. The results demonstrate that Tnfr1-/- mice have important gene expression changes, including reduced expression of Il1b, a marker of the proinflammatory "weaning reaction" that is required for establishment of mucosal tolerance in later life. TNFR1 therefore has key roles in colonic mucosal homeostasis in early life.

2020-08-05 | GSE155654 | GEO

Evidence-based treatment of patients with acute large bowel obstruction caused by colon cancer of the left colon: Applying a clinical decision guideline

Project description:Interventions: 1. Patients younger than 70 years will have surgical resection. Exceptions can be made for those who have (1) an indication for neo-adjuvant treatment, (2) severe comorbidities, and (3) incurable metastatic disease; they should receive a decompressing intervention. 2. Patients aged 70 years and older without incurable metastatic disease will initially have non-resectional decompression followed by elective resection (bridge to surgery treatment): A) Patients with a malignant stenosis < 40 mm are eligible for colonic stent placement, which will be performed by an experienced gastroenterologist. B) If stent insertion failed, if stricture characteristics are unfavourable for stent placement, or if systemic anti-angiogenic therapy is intended, a minimally invasive transverse loop colostomy is constructed. Patients eligible for elective resection will be operated at least 7 days after initial decompression and no later than 4 weeks after initial presentation. 3. Patients of all ages with incurable extensive metastatic disease or patients who are unfit to undergo surgical resection will be treated palliatively by stent placement or a diverting colostomy. Patients who are fit enough to have palliative chemotherapy are best treated with a colostomy in case anti-angiogenic therapy will be administered because of the risk of tumour perforation when having a stent in situ. Primary outcome(s): In-hospital and 30-day mortality rate in the elderly patients (≥ 70 years). Study Design: Non-randomized controlled trial, Open (masking not used), N/A , unknown, Other

| 18885 | ecrin-mdr-crc

Gene expression response to implanted drug (paclitaxel)-eluting or bare metal stents in denuded human LIMA arteries

Project description:[original title] Gene expression response to the implantation of drug (paclitaxel)-eluting or bare metal stents in denuded human LIMA arteries. Different clinical outcomes have been observed for paclitaxel-eluting and bare metal cardiovascular stents. The aim of this project was to identify genes that might be associated with the observed clinical outcomes. Human left internal mammary artery (LIMA) was divided into three segments and and two of the segments were fitted with either a paclitaxel-eluting stent or a bare metal stent. The experiment includes three groups: control, paclitaxel-eluting stent, and bare metal stent, respectively. Each group includes four biological replicates (patients 1, 2, 4 and 5).

2010-03-07 | E-GEOD-19136 | biostudies-arrayexpress

XTX301, a tumor-activated Interleukin-12 has the potential to widen the therapeutic index of IL-12 treatment for solid tumors as evidenced by pre-clinical studies.

Project description:Interleukin-12 (IL-12) is a proinflammatory cytokine, that has shown promising anti-tumor activity in mice and humans by promoting the recruitment and activation of immune cells in tumors. However, the systemic intravenous administration of IL-12 has been accompanied by considerable toxicity, prompting interest in researching alternatives to have preferential IL-12 bioactivity in the tumor. We have generated XTX301, a half-life extended IL-12 molecule fused to the human Fc protein via a protease cleavable linker and pharmacologically inactivated by an interleukin-12 receptor subunit beta 2 (IL-12Rβ2) masking domain. Intravenous administration of a mouse surrogate molecule (mXTX301) demonstrated significant tumor growth inhibition in mouse models of colorectal cancer and melanoma without causing systemic toxicities. Here, we performed gene expression analysis of tumor samples to characterize the mechanism of action of mXTX301. MC38 tumor-bearing mice were treated with vehicle, mXTX301, or an unmasked positive control. A comprehensive examination of global gene expression revealed a similar pattern of molecular changes for mXTX301 and unmasked control on Day 4 and Day 7 compared to vehicle, with both molecules inducing the upregulation of several immune-related genes such as Stat1, Il12rb1, Irf1 and Cxcl9 . Thus, mXTX301 demonstrated pharmacodynamic effects in mouse tumors that are consistent with known IL-12 biology.

2023-12-05 | GSE237982 | GEO

Gene expression profiling of 3T3 fibroblast cells cultured with degradable metallic materials

Project description:Metals have been used for coronary artery stent materials in order to prevent stenosis caused by atherosclerosis. Degradable metallic materials (DMMs) are considered to be useful to avoid in-stent restenosis and late thrombosis. A new DMM, Fe-35Mn alloy, was fabricated through powder metallurgy in order to satisfy the ideal criteria of cardiovascular stent made of DMM. Since in-stent restenosis is mediated by the extracellular matrix production, which is mostly regulated by fibroblasts, the gene expression profile of 3T3 fibroblasts in the presence of Fe-35Mn alloy was then investigated. The mechanism of cellular responses in the presence of DMM is then expected to be clearly described through the gene profiling experiment.

2010-07-24 | GSE22794 | GEO

Endovascular Device for Endothelial Cell Sampling

Project description:We have developed an endovascular catheter-based device for sampling of the endothelium, intended for RNA-seq analysis. With an outer diameter of 0.23 mm it is capable of reaching peripheral vessels for endothelial sampling, and favourably compares to other approaches with stent retrievers or similar tools. Here, we have collected samples from liver and kidney vessels from swine and performed RNA-sequencing to validate the sample quality.

2022-08-21 | GSE197756 | GEO

Study on the effectiveness of stenting for obstructive colorectal cancer at Niigata City Hospital

Project description:Primary outcome(s): Postoperative recurrence rate through 8 years after introduction of colorectal stent at Niigata City General Hospital.

| 2655505 | ecrin-mdr-crc

A study on colonic decompression as bridge to surgery for obstructive colon cancer.

Project description:Interventions: Primary tumor resection within 3-30 days after stent(Nite-S colonic stent) placement. Primary outcome(s): Complication rate during decompression and perioperative period. Study Design: Single arm Non-randomized

| 2649027 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data